Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMichael Ament, Sheena K. Aurora, Mallikarjuna Rettiganti et al.|The Journal of Headache and Pain|2021Cited by 43
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc AnalysisPatricia Pozo‐Rosich, Eric Pearlman, Karen Samaan et al.|Advances in Therapy|2021Cited by 12